相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
Richard T. Maziarz et al.
BONE MARROW TRANSPLANTATION (2021)
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser et al.
BLOOD (2021)
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
Antonio M. Jimenez Jimenez et al.
BONE MARROW TRANSPLANTATION (2021)
Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
Jennifer M. Yoest et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms
Paula Aguirre-Ruiz et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome
Thierry Guillaume et al.
BONE MARROW TRANSPLANTATION (2019)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
Richard F. Schlenk et al.
BLOOD (2019)
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT
Christoph Schmid et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
Christina Rautenberg et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report
Jakob R. Passweg et al.
BONE MARROW TRANSPLANTATION (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Prognostic Significance of Measurable (Minimal) Residual Disease in Acute Myeloid Leukemia
Francesco Buccisano et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention
Xiao-Dong Mo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia
J. Frazer et al.
CURRENT ONCOLOGY (2017)
Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation
Z. Jedlickova et al.
BONE MARROW TRANSPLANTATION (2016)
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
Charles Craddock et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
P. Tsirigotis et al.
BONE MARROW TRANSPLANTATION (2016)
Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions-A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
Thomas Schroeder et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation
Tanja Stahl et al.
EXPERIMENTAL HEMATOLOGY (2015)
Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+donor cell chimerism analysis
Joerg Christian Hoffmann et al.
ANNALS OF HEMATOLOGY (2014)
Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT
X-Y Qin et al.
BONE MARROW TRANSPLANTATION (2014)
Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic. Stem Cell Transplantation
Gita Thanarajasingam et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation
A. Antar et al.
BONE MARROW TRANSPLANTATION (2013)
CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT
F. Rosenow et al.
BONE MARROW TRANSPLANTATION (2013)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
Chen-Hua Yan et al.
BLOOD (2012)
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U. Platzbecker et al.
LEUKEMIA (2012)
Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation
Eva Rettinger et al.
BLOOD (2011)
Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced- intensity conditioning
T. Lange et al.
LEUKEMIA (2011)
Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions
Darius Sairafi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes
Nicolaus Kroeger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Maintenance Therapy With Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Marcos de Lima et al.
CANCER (2010)
Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation
Martin Bornhaeuser et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome
C Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation
R Zeiser et al.
LEUKEMIA (2005)
How and when should we monitor chimerism after allogeneic stem cell transplantation?
P Bader et al.
BONE MARROW TRANSPLANTATION (2005)
Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+donor cell chimerism analysis
C Scheffold et al.
LEUKEMIA (2004)
Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms
F Maas et al.
LEUKEMIA (2003)
Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation
J Mattsson et al.
LEUKEMIA (2001)
分享论文
